In early October, the World Health Organization (WHO) prequalified a fourth human papillomavirus (HPV) vaccine, Cecolin, for single-dose use. The shift from a 2-dose HPV vaccine regimen to an alternative, off-label 1-dose injection schedule, recommended by the WHO in 2022, will help address the global supply shortages that have historically left individuals from low- and middle-income countries unprotected, the organization said.
